The 5 analysts offering 12-month price forecasts for ADMA Biologics Inc have a median target of 5.00, with a high estimate of 10.00 and a low estimate of 3.00. The median estimate represents a +263.64% increase from the last price of 1.38.
The current consensus among 5 polled investment analysts is to Buy stock in ADMA Biologics Inc. This rating has held steady since November, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.10
Reporting Date Mar 24
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.